Literature DB >> 17542052

New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection.

Sheila C Dollard1, Scott D Grosse, Danielle S Ross.   

Abstract

Congenital CMV is a major cause of neurological and sensory impairment in children. Reliable estimates of the prevalence of permanent sequelae and mortality associated with congenital CMV are needed to guide development of education and prevention programmes and to gauge the financial costs associated with this disease. To calculate such estimates, this review used data solely from studies in which children with congenital CMV were identified through universal screening. Based on 15 studies with a total of 117 986 infants screened, the overall CMV birth prevalence estimate was 0.7%. The percentage of infected children with CMV-specific symptoms at birth was 12.7%. The percentage of symptomatic children with permanent sequelae was 40-58%. The percentage of children without symptoms at birth who developed permanent sequelae was estimated to be 13.5%. The true burden of congenital CMV infection is unclear because data on important outcomes, such as visual impairment, are lacking and follow-up of infected children has been too short to fully identify late-onset sequelae. Therefore, the estimates of permanent sequelae associated with congenital CMV presented here are likely underestimates. Future studies should extend follow-up of CMV-infected children identified through universal screening and include the evaluation of visual impairment.

Entities:  

Mesh:

Year:  2007        PMID: 17542052     DOI: 10.1002/rmv.544

Source DB:  PubMed          Journal:  Rev Med Virol        ISSN: 1052-9276            Impact factor:   6.989


  304 in total

1.  Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees.

Authors:  Ravit Arav-Boger; Sallie R Permar; Cody S Nelson; Diana Vera Cruz; Melody Su; Guanhua Xie; Nathan Vandergrift; Robert F Pass; Michael Forman; Marie Diener-West; Katia Koelle
Journal:  J Virol       Date:  2019-02-19       Impact factor: 5.103

Review 2.  Public health and laboratory considerations regarding newborn screening for congenital cytomegalovirus.

Authors:  Sheila C Dollard; Mark R Schleiss; Scott D Grosse
Journal:  J Inherit Metab Dis       Date:  2010-06-08       Impact factor: 4.982

3.  Cytomegalovirus survival on common environmental surfaces: opportunities for viral transmission.

Authors:  Jennifer D Stowell; Daniela Forlin-Passoni; Erica Din; Kay Radford; Denise Brown; Audrey White; Sheri L Bate; Sheila C Dollard; Stephanie R Bialek; Michael J Cannon; D Scott Schmid
Journal:  J Infect Dis       Date:  2011-11-23       Impact factor: 5.226

4.  Cytomegalovirus (CMV) seroprevalence in pregnant women, bone marrow donors and adolescents in Germany, 1996-2010.

Authors:  Gisela Enders; Anja Daiminger; Lisa Lindemann; Frank Knotek; Ursula Bäder; Simone Exler; Martin Enders
Journal:  Med Microbiol Immunol       Date:  2012-03-08       Impact factor: 3.402

Review 5.  Noncoding RNPs of viral origin.

Authors:  Joan Steitz; Sumit Borah; Demian Cazalla; Victor Fok; Robin Lytle; Rachel Mitton-Fry; Kasandra Riley; Tasleem Samji
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-03-01       Impact factor: 10.005

6.  Valnoctamide Inhibits Cytomegalovirus Infection in Developing Brain and Attenuates Neurobehavioral Dysfunctions and Brain Abnormalities.

Authors:  Sara Ornaghi; Lawrence S Hsieh; Angélique Bordey; Patrizia Vergani; Michael J Paidas; Anthony N van den Pol
Journal:  J Neurosci       Date:  2017-06-19       Impact factor: 6.167

7.  Electrochemical detection of a single cytomegalovirus at an ultramicroelectrode and its antibody anchoring.

Authors:  Jeffrey E Dick; Adam T Hilterbrand; Aliaksei Boika; Jason W Upton; Allen J Bard
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-13       Impact factor: 11.205

Review 8.  Cochlear Implants and Children with Vestibular Impairments.

Authors:  Sharon L Cushing; Blake C Papsin
Journal:  Semin Hear       Date:  2018-07-20

9.  Valganciclovir Use Among Commercially and Medicaid-insured Infants With Congenital CMV Infection in the United States, 2009-2015.

Authors:  Jessica Leung; Sheila C Dollard; Scott D Grosse; Winnie Chung; ThuyQuynh Do; Manisha Patel; Tatiana M Lanzieri
Journal:  Clin Ther       Date:  2018-02-04       Impact factor: 3.393

10.  Spectrum of disease and outcome in children with symptomatic congenital cytomegalovirus infection.

Authors:  A Mackenzie Dreher; Nitin Arora; Karen B Fowler; Zdenek Novak; William J Britt; Suresh B Boppana; Shannon A Ross
Journal:  J Pediatr       Date:  2014-01-14       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.